Greenwich LifeSciences, Inc.
GLSI
$16.80
$0.422.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.99M | 1.88M | 1.86M | 2.53M | 2.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.87M | 21.61M | 18.66M | 20.42M | 18.98M |
| Operating Income | -21.87M | -21.61M | -18.66M | -20.42M | -18.98M |
| Income Before Tax | -21.68M | -21.48M | -18.57M | -20.31M | -18.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.68 | -21.48 | -18.57 | -20.31 | -18.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.68M | -21.48M | -18.57M | -20.31M | -18.83M |
| EBIT | -21.87M | -21.61M | -18.66M | -20.42M | -18.98M |
| EBITDA | -21.87M | -21.61M | -18.66M | -20.42M | -18.97M |
| EPS Basic | -1.53 | -1.54 | -1.36 | -1.53 | -1.43 |
| Normalized Basic EPS | -0.96 | -0.96 | -0.85 | -0.96 | -0.89 |
| EPS Diluted | -1.53 | -1.54 | -1.36 | -1.53 | -1.43 |
| Normalized Diluted EPS | -0.96 | -0.96 | -0.85 | -0.96 | -0.89 |
| Average Basic Shares Outstanding | 56.78M | 55.53M | 54.13M | 53.33M | 52.83M |
| Average Diluted Shares Outstanding | 56.78M | 55.53M | 54.13M | 53.33M | 52.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |